title: The effects of iloprost on lung injury induced by skeletal muscle ischemia-reperfusion.
abstract: OBJECTIVE
  The aim of this study was to investigate the effects of iloprost (I) on lung injury as a remote organ following skeletal muscle ischemia-reperfusion injury in a rat model.
  
  
  METHODS
  Twenty-four Wistar Albino rats were randomized into four groups (n = 6). Laparotomy was performed in all groups under general anesthesia. Only laparotomy was applied in Group S (Sham). Ischemia reperfusion group (Group I/R) underwent ischemia and reperfusion performed by clamping and declamping of the infrarenal abdominal aorta for 120 minutes. Group iloprost (Group I) received intravenous infusion of iloprost 0.5 ng/kg/min, without ischemia and reperfusion. Group I/R/I received intravenous infusion of iloprost 0.5 ng/kg/min immediately after 2 hours of ischemia. At the end of the study, lung tissue was obtained for determining total oxidant status (TOS) and total antioxidant status (TAS) levels, histochemical and immunohistochemical determination.
  
  
  RESULTS
  Diffuse lymphocyte infiltration was detected in immunohistochemical examination of lung tissue in Group I/R. The connective tissue around bronchi, bronchioles and vessel walls was found to be increased. Although minimal local lymphocyte infiltration was detected in some fields in Group I/R/I, the overall tissue was found to be similar to Group S. iNOS expression was significantly higher in Group I/R, when compared with Group S and significantly lower in Group I/R/I compared to Group I/R.TOS levels were significantly higher in Group I/R, when compared with groups S and I (p = 0.028, p = 0.016, respectively) and significantly lower in group I/R/I, when compared with Group I/R (p = 0.048). TAS levels were significantly higher in Group I/R, when compared with groups S, I (p = 0.014, p = 0.027, respectively) and significantly lower in Group I/R/I, when compared with Group I/R (p = 0.032).
  
  
  CONCLUSIONS
  These results indicate that administration of iloprost may have protective effects against ischemia reperfusion injury (Fig. 8, Tab. 1, Ref. 30)
authors: D
authors: D
authors: Erer
authors: A D
authors: AD
authors: Dursun
authors: G L
authors: GL
authors: Oktar
authors: E
authors: E
authors: Iriz
authors: M H
authors: MH
authors: Zor
authors: C
authors: C
authors: Elmas
authors: T
authors: T
authors: Donmez
authors: M
authors: M
authors: Kirisci
authors: F M
authors: FM
authors: Comu
authors: M
authors: M
authors: Arslan
mesh_terms: D000328:Adult; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D006801:Humans; D016285:Iloprost / Q000494:pharmacology*; D007511:Ischemia / Q000150:complications*; D055370:Lung Injury / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D018482:Muscle, Skeletal / Q000098:blood supply*; D020011:Protective Agents / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000150:complications*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D020011:Protective Agents; D014665:Vasodilator Agents; D016285:Iloprost